Patients increasingly arrive with questions about Khavinson peptides they have read about online. This guide summarises where the research came from, what level of evidence supports it, how the products are regulated in the United States, and how to counsel a patient who asks.
The story begins in Leningrad in the 1970s and 1980s, at the Military Medical Academy, where a group of researchers including Vladimir Khavinson and Vyacheslav Morozov studied polypeptide extracts of animal organs. Two of the earliest preparations were an extract of the thymus, later known as Thymalin, and an extract of the pineal gland, later known as Epithalamin. According to the group's own publications, these extracts were studied in the Soviet Union as pharmaceutical preparations, and a research institute, the St. Petersburg Institute of Bioregulation and Gerontology, was later founded to continue the work.
From the 1990s onward, the group moved from complex extracts to very short synthetic peptides, typically two to four amino acids long, which they described as the active fractions of the original extracts. The general hypothesis they advanced is that each tissue type produces its own short peptides known as peptide bioregulators, which participate in regulating gene expression within that tissue. The term has since spread well beyond the original literature.
For a clinician, the useful question is not "is this interesting?" but "what kind of evidence exists, and how much weight does it carry?" The group's own position is summarised in a 2021 systematic review in Molecules, which collects the cell-culture, animal and clinical work on short peptides and gene expression. Read critically, the record looks like this:
In vitro and animal studies: the largest part of the published record, including cell-culture work on gene expression and a number of rodent studies. Mechanistic and hypothesis-generating.
Human studies: a number of clinical studies, mostly conducted in Russia, many with small sample sizes, open-label designs and limited description of randomisation and blinding. Several were published only in Russian-language journals.
Independent replication: limited. Most of the human data originates from a single research network, which is a recognised source of bias regardless of the field.
Large multi-centre randomised trials: none that would meet the standard a regulator or a guideline committee would require.
In short, the concept sits at the hypothesis stage of the evidence pyramid. That is not a dismissal; many established interventions started there. It is a description of how much confidence the data currently justify, which is the figure a patient deserves to hear. It is also worth separating this literature from the very different conversation about injectable anti-ageing peptides such as BPC-157: those are research compounds, usually injected, with their own evidence gaps and safety questions, and patients often conflate the two.
In the US, peptide-based products derived from this research are marketed as dietary supplements, not drugs. The manufacturer's range is sold under the name GARMONIA Khavinson peptides, and the same products appear under various retailer names online. Under the Dietary Supplement Health and Education Act, such products may not claim to diagnose, treat, cure or prevent any disease, are not reviewed by the FDA for efficacy before sale, and are the manufacturer's responsibility with respect to safety and labelling; a useful primer on how supplements are made and regulated covers the GMP and contract-manufacturing side of that system. A patient who has read a claim that a peptide supplement "treats" a condition has read a claim that is not permitted, which is worth pointing out.
Most patients who raise the topic are not looking for permission so much as for an honest assessment. A few points tend to cover it:
Describe the evidence accurately. "Early-stage research, mostly from one group, not confirmed in large independent trials" is both truthful and understandable.
Ask what the patient is hoping to achieve. Often there is an underlying concern, such as sleep, fatigue or a family history, that can be addressed directly.
Check for interactions and contraindications. Interaction data for these products are essentially absent. Caution is warranted in pregnancy and breastfeeding, in patients on immunomodulating or hormonal therapy, and in anyone with a condition under active treatment. The same questions that apply to supplement timing and drug interactions in general apply here, with less data to answer them.
Make clear that supplements do not replace treatment. The greatest practical risk with any unproven product is delay or substitution of care that works.
Document the conversation. As with any supplement use, note it in the record.
The broader scientific question behind this research, how short signalling peptides contribute to intercellular communication and how that communication changes with age, is a legitimate and active field well outside the original group. Being able to separate that legitimate question from the specific, still-unproven claims attached to particular products is exactly the kind of judgement patients rely on clinicians for.
This article is intended for educational purposes only and does not constitute medical advice or a recommendation to use any product. Dietary supplements are not intended to diagnose, treat, cure or prevent any disease.
MBTpg/MSM
